HCPCS code S0142 – Colistimethate sodium

Key takeaways

HCPCS code S0142 describes colistimethate sodium inhalation solution administered through durable medical equipment (DME), concentrated form, billed per milligram.

S0142 is a temporary national S-code: Medicaid and private payers accept it, but Medicare Part B does not typically reimburse HCPCS S-codes.

Billing errors most often come from unit reporting: Each unit billed must equal exactly one milligram of colistimethate sodium administered.

Practice management software like Pabau helps DME suppliers track per-unit drug billing, payer rules, and HCPCS documentation in one place.

• “Inhalation solution”: Separates this code from parenteral colistimethate formulations.
• “Administered through durable medical equipment”: Ties the claim to a qualifying nebulizer.
• “Concentrated form, per mg”: Sets the unit of measure that controls how many units appear on the claim.

DME administration: What qualifies for S0142 billing

S0142 is billable only when the inhalation solution reaches the patient through a qualifying nebulizer system. A small-volume, large-volume, or ultrasonic nebulizer can all qualify. The equipment itself has to be separately enrolled and billed through the DME benefit.

Billing S0142 for oral or parenteral colistimethate sodium is incorrect, and the claim will be rejected.

DME suppliers must hold active Medicare DMEPOS accreditation even for Medicaid and private payer claims. Most state Medicaid programs and commercial payers mirror the CMS supplier standards. The supplier’s National Provider Identifier (NPI) has to appear on the claim form.

The treating physician’s order must specify the inhalation route, the drug concentration, and the prescribed dose in milligrams. Incomplete physician orders are the most common upstream cause of S0142 denials.

• Qualifying equipment: Small-volume nebulizer, large-volume nebulizer, ultrasonic nebulizer enrolled under the DME benefit
• Required documentation: Physician order specifying inhalation route, drug concentration, and prescribed dose in mg
• Supplier requirement: Active DME/DMEPOS accreditation and NPI on file with the payer
• Common billing error: Billing S0142 for parenteral or oral colistimethate sodium rather than nebulized inhalation

Payer coverage: Medicaid, private insurers, and Medicare

State Medicaid programs and commercial insurers pay S0142. Traditional Medicare Part B does not, because CMS created the S-series for non-Medicare payers only. Part B will not process an S0142 claim under standard fee-for-service rules.

For a patient who is dually eligible, Medicaid acts as the secondary payer. Route the claim through the Medicaid billing system rather than Medicare’s.

State Medicaid programs are the primary payer for S0142. Coverage policies and reimbursement rates vary by state. Verify the current fee schedule rate directly with the state Medicaid agency before submitting.

Many commercial and private insurers also accept S-codes, though prior authorization requirements differ by plan. Checking the patient’s eligibility and benefits before dispensing through DME heads off after-the-fact denials.

Billing guidelines for HCPCS code S0142

The per-milligram billing unit is where S0142 claims most often go wrong. Each unit reported must represent exactly one milligram of colistimethate sodium administered to the patient. If the physician prescribes 150 mg per dose, bill 150 units.

Rounding up or estimating units without supporting documentation creates fraud risk under False Claims Act standards. The quantity billed has to reconcile against the physician’s order, the dispensing record, and the administration record.

Understanding what makes a clean claim is the starting point for S0142 submissions. A complete claim carries the following elements on the CMS-1450 (UB-04) or CMS-1500 form, depending on the billing entity:

• HCPCS code S0142 in the procedure code field
• Units equal to the exact milligrams administered (not prescribed dose units)
• Date of service matching the administration date
• Diagnosis code(s) establishing medical necessity (see ICD-10 section below)
• Treating physician NPI and ordering physician NPI where required
• Place of service code appropriate to the care setting
• DME supplier NPI and accreditation information

Documentation requirements extend beyond the claim form. During post-payment review, a payer may ask for:

• The physician order
• The treatment record showing the nebulizer administration
• Proof of DME supplier accreditation

A consistent documentation routine for every S0142 dispensing episode cuts the rework a billing team absorbs later.

OPPS status and outpatient payment system data

Under the Outpatient Prospective Payment System (OPPS), CMS assigns status indicators that decide how an outpatient facility claim is processed and paid. Hospital outpatient billers should read S0142’s indicator in the current OPPS addendum rather than trust a stored value. Those designations can change with each annual OPPS final rule.

The Integrated Outpatient Code Editor (IOCE) applies edit logic to outpatient facility claims. It checks the coding, the diagnosis pairing, and the modifiers. A claim that fails an IOCE edit returns with Claim Adjustment Reason Codes (CARCs) naming the specific failure.

Reviewing those edits before submission prevents rework. The AAPC HCPCS code reference publishes current code attribute data, including OPPS indicators.

ICD-10-CM diagnosis codes commonly paired with S0142

Every S0142 claim needs a diagnosis code that establishes medical necessity for inhaled colistimethate sodium. The treating physician documents the underlying condition in the medical record. The code on the claim must reflect that documentation.

Two clinical scenarios drive most S0142 use. The first is cystic fibrosis with pulmonary involvement. The second is gram-negative respiratory infection in patients with chronic lung disease or structural airway abnormalities.

The table below lists the ICD-10-CM codes most frequently paired with S0142. Each one reflects a condition for which inhaled colistimethate sodium is commonly prescribed. The treating provider still has to document medical necessity separately. Coders should not assign a diagnosis code without supporting clinical documentation.

Cystic fibrosis (E84.0) is the dominant indication. Inhaled colistimethate sodium suppresses chronic Pseudomonas aeruginosa colonization in CF patients, which reduces exacerbation frequency. For non-CF patients, the indication usually involves multidrug-resistant gram-negative organisms.

Inhaled delivery reaches the respiratory tract directly and limits systemic toxicity. Coders should name the specific organism when the record documents it, since that strengthens medical necessity at review. Confirm the exact subcategory in the ICD-10-CM code library before assigning it.

Clinical context: What is colistimethate sodium and who receives it?

Colistimethate sodium is the prodrug form of colistin, a polymyxin-class antibiotic. It works against aerobic gram-negative bacteria, including Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. Clinicians reach for it as a last-resort agent once multidrug-resistant organisms have exhausted first-line options.

The inhaled route reaches the pulmonary epithelial surface directly. That achieves high local drug concentrations while reducing the systemic exposure that drives nephrotoxicity with intravenous colistin.

Knowing the patient population helps coders tell when S0142 applies and when a different code does. Three groups account for most use:

• Cystic fibrosis patients: Chronic Pseudomonas colonization is almost universal in adults with CF. Inhaled colistimethate sodium may be prescribed for long-term suppressive therapy or acute exacerbation management, often alongside other inhaled antibiotics such as tobramycin.
• Non-CF bronchiectasis patients: Structural lung disease patients with recurrent gram-negative infections may receive inhaled colistimethate as part of a rotating inhaled antibiotic regimen.
• ICU or post-hospitalization patients: Patients transitioning from IV colistin therapy for MDR gram-negative pneumonia may continue inhaled colistimethate through a home DME nebulizer following discharge.

Coders do not prescribe or recommend treatment. This clinical context exists so the code lands on the right claims, with a diagnosis pairing the treating physician documented. Every code on a claim has to be supported by the medical record.

Related HCPCS codes for inhaled antibiotics and DME

Several adjacent HCPCS codes appear alongside S0142 in DME and respiratory drug billing. Knowing which code covers which drug and formulation prevents miscoding across the inhaled antibiotic category. It also keeps the claim set complete when several inhaled medications go out in the same episode.

J7682 and J7685 deserve particular attention from CF billing teams. Tobramycin and colistimethate are sometimes alternated on a monthly rotation. Both codes then appear in the same patient record across different dates of service.

Verify the dispensing record against the code submitted for each date. Billing J7682 on a date when colistimethate went out is a coding error, and payers flag it during retrospective audits.

Common denial patterns and how to resolve them

S0142 claims deny for predictable reasons. Catching the pattern before submission costs far less than appealing after the fact. The three most frequent triggers are missing prior authorization, unit count discrepancies, and wrong payer routing.

• Prior authorization missing: Many Medicaid plans and commercial payers require PA for inhaled antibiotics. Obtain authorization before dispensing and document the authorization number on the claim.
• Unit count mismatch: The billed units do not match the administered milligrams documented in the treatment record. Reconcile dispensing logs with claim units before submission.
• Wrong payer routing: Submitting S0142 to Medicare Part B fee-for-service. Route these claims to Medicaid or the commercial plan instead.
• Incomplete physician order: The order does not specify inhalation route, concentration, or milligram dose. Contact the prescribing physician to amend the order before resubmission.
• Diagnosis not supporting medical necessity: The ICD-10 code on the claim does not align with the documented clinical indication for inhaled colistimethate. Review the record and correct the diagnosis pairing.

Each of those denials has a step in the dispensing workflow that prevents it. The checkpoints below map one to the other.

Billing teams handling per-unit drug codes lean on claims management software to hold those checkpoints in one place. That keeps the order, the authorization, and the unit count together when a payer asks for them.

How Pabau keeps S0142 documentation claim-ready

Most DME suppliers and specialty practices track an S0142 episode across three disconnected places. The physician order sits in a fax folder. The authorization number lives in a spreadsheet, and the administered dose is written on a treatment note.

Reconciling units at billing time then means opening all three. Pabau, our practice management software, keeps those records against the patient instead. Structured treatment forms capture the inhalation route, the concentration, and the milligrams given at each visit.

Insurance details and authorization references sit on the same patient record, so the biller reads one screen rather than three. The outcome is a shorter reconciliation step and fewer claims returned over a unit count nobody can trace.

When a payer requests records during post-payment review, the documentation is already attached to the episode it belongs to.

Simplify HCPCS billing documentation

Pabau’s claims management tools help DME suppliers and specialty practices track per-unit drug billing. Payer-ready documentation stays on the patient record, which reduces rejections on codes like S0142.

Book a demo

Conclusion

Two checks decide whether an S0142 claim survives. The first is the payer, since a claim sent to traditional Medicare Part B is dead on arrival. The second is the milligram count, which turns into an audit finding months later if it cannot be traced.

The rest is routine. Build the documentation habit once, at the point of dispensing, and the claim assembles itself from records that already exist. Book a demo to see how Pabau keeps physician orders, authorizations, and administered doses on one patient record.

Continue your research

Want to reduce claim rejections across your HCPCS billing? What is medical billing explains the full lifecycle from documentation through reimbursement.

Seeing denials on drug claims? Denial management in healthcare covers systematic approaches to reducing and recovering rejected claims.

Need a billing compliance checklist? Medical billing compliance outlines documentation and audit requirements for specialty drug billing.

Frequently asked questions